Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors

被引:145
作者
Zhou, Jiangbing [1 ,2 ]
Patel, Toral R. [2 ]
Fu, Michael [1 ]
Bertram, James P. [1 ]
Saltzman, W. Mark [1 ]
机构
[1] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06511 USA
关键词
PLGA; Nanoparticle; Gene delivery; RNA interference; SMALL INTERFERING RNA; PLASMID DNA; NUCLEAR-PORE; CELLS; TRANSFECTION; EXPRESSION; MECHANISM; PEPTIDES; THERAPY; RELEASE;
D O I
10.1016/j.biomaterials.2011.09.061
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Therapies based on RNA interference, using agents such as siRNA, are limited by the absence of safe. efficient vehicles for targeted delivery in vivo. The barriers to siRNA delivery are well known and can be individually overcome by addition of functional modules, such as conjugation of moieties for cell penetration or targeting. But, so far, it has been impossible to engineer multiple modules into a single unit. Here, we describe the synthesis of degradable nanoparticles that carry eight synergistic functions: 1) polymer matrix for stabilization/controlled release; 2) siRNA for gene knockdown; 3) agent to enhance endosomal escape; 4) agent to enhance siRNA potency; 5) surface-bound PEG for enhancing circulatory time; and surface-bound peptides for 6) cell penetration; 7) endosomal escape; and 8) tumor targeting. Further, we demonstrate that this approach can provide prolonged knockdown of PLK1 and control of tumor growth in vivo. Importantly, all elements in these octa-functional nanoparticles are known to be safe for human use and each function can be individually controlled, giving this approach to synthetic RNA-loaded nanoparticles potential in a variety of clinical applications. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:583 / 591
页数:9
相关论文
共 37 条
[12]   Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting [J].
Fahmy, TM ;
Samstein, RM ;
Harness, CC ;
Saltzman, WM .
BIOMATERIALS, 2005, 26 (28) :5727-5736
[13]   CELLULAR UPTAKE OF THE TAT PROTEIN FROM HUMAN IMMUNODEFICIENCY VIRUS [J].
FRANKEL, AD ;
PABO, CO .
CELL, 1988, 55 (06) :1189-1193
[14]   Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway [J].
Frankel, Paul ;
Pellet-Many, Caroline ;
Lehtolainen, Pauliina ;
D'Abaco, Giovanna M. ;
Tickner, Michelle L. ;
Cheng, Lili ;
Zachary, Ian C. .
EMBO REPORTS, 2008, 9 (10) :983-989
[15]   Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA [J].
Heidel, Jeremy D. ;
Yu, Zhongping ;
Liu, Joanna Yi-Ching ;
Rele, Shyam M. ;
Liang, Yongchao ;
Zeidan, Ryan K. ;
Kornbrust, Douglas J. ;
Davis, Mark E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (14) :5715-5721
[16]   Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma [J].
Hu-Lieskovan, S ;
Heidel, JD ;
Bartlett, DW ;
Davis, ME ;
Triche, TJ .
CANCER RESEARCH, 2005, 65 (19) :8984-8992
[17]   Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration [J].
Jones, DH ;
Corris, S ;
McDonald, S ;
Clegg, JCS ;
Farrar, GH .
VACCINE, 1997, 15 (08) :814-817
[18]   Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice [J].
Judge, Adam D. ;
Robbins, Marjorie ;
Tavakoli, Iran ;
Levi, Jasna ;
Hu, Lina ;
Fronda, Anna ;
Ambegia, Ellen ;
McClintock, Kevin ;
MacLachlan, Ian .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (03) :661-673
[19]  
Lavik EB, 2001, J BIOMED MATER RES, V58, P291, DOI 10.1002/1097-4636(2001)58:3<291::AID-JBM1019>3.3.CO
[20]  
2-E